Court rules Remicade patent is invalid
The U.S. District Court in Massachusetts Federal Court has ruled a patent for Remicade, a top-selling rheumatoid arthritis drug sold by Johnson& Johnson subsidiary Janssen Biotech, is invalid.
The court sided with the request for a summary judgement in the patent infringement dispute filed by Celltrion Healthcare Co. Ltd and Pfizer-owned Hospira Healthcare Corp., which want to sell a biosimilar version of the product.
Johnson& Johnson (NYSE; JNJ) issued a statement following the ruling in which … (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 17, 2016 Category: Pharmaceuticals Authors: John George Source Type: news
J & J says court finds Remicade patent invalid
(Reuters) - Johnson& Johnson said a U.S. court had held its patent for autoimmune drug Remicade invalid, ruling in favor of two companies seeking to bring a cheaper version of the blockbuster drug to market. (Source: Reuters: Health)
Source: Reuters: Health - August 17, 2016 Category: Consumer Health News Tags: healthNews Source Type: news
The Efficacy and Safety of CT-P13 vs Infliximab in RA The Efficacy and Safety of CT-P13 vs Infliximab in RA
CT-P13, a biosimilar of reference infliximab, may be a safe and effective treatment option for patients with active rheumatoid arthritis.Arthritis Research & Therapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 9, 2016 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news
India's Reliance Grabs Rights to Biosimilars in Epirus Bankruptcy
Reliance Life Sciences, the biopharmaceutical unit of India-based Reliance Industries, has acquired the global rights for biosimilars of Infliximab. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - July 28, 2016 Category: Pharmaceuticals Source Type: news
Reliance Life gains global rights for copies of Infliximab
< a href="http://economictimes.indiatimes.com/industry/healthcare/biotech/reliance-life-gains-global-rights-for-copies-of-infliximab/articleshow/53389127.cms" > < img width="100" height="75" border="0" hspace="10" align="left" src="http://img.etimg.com/photo/53389127.cms" / > < /a > For Infliximab, Reliance Life Sciences had completed process development, manufacturing, clinical trials in India and obtained marketing approval last year. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - July 25, 2016 Category: Pharmaceuticals Source Type: news
AS Responds Better than AxSpA to Infliximab (CME/CE)
(MedPage Today) -- ASAS partial remission rate of 70% in AS patients (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - July 25, 2016 Category: Geriatrics Source Type: news
Histologic Remission Seen With Infliximab Treatment in Ulcerative ColitisHistologic Remission Seen With Infliximab Treatment in Ulcerative Colitis
Infliximab can induce histological remission in ulcerative colitis (UC) patients, new findings show. Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - July 8, 2016 Category: Surgery Tags: Gastroenterology News Source Type: news
Side Effects May Include: HLH
It was June 2015, and the whole thing had started as hot flashes and a headache at a friend's summer kick-off party. He must've put in some funky ingredients in the punch, I thought to myself after. Or maybe I just drank too much of it?
As the days went on the flashes turned into out-of-this-world, 104-105 degree fevers, followed by bed-drenching sweats, then full-on teeth-chattering shivers. I felt like a lobster reaching full boil, only to be transferred to a cryogenic chamber. This went on for almost two weeks. I dreaded the nights the most, when the fevers were at their worst. I couldn't sleep. I went to the emergency...
Source: Healthy Living - The Huffington Post - July 6, 2016 Category: Consumer Health News Source Type: news
infliximab, Remicade
Title: infliximab, RemicadeCategory: MedicationsCreated: 12/13/1999 12:00:00 AMLast Editorial Review: 6/30/2016 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - June 30, 2016 Category: Rheumatology Source Type: news
European experience: Biosimilar infliximab works as well as Remicade for IBD
SAN DIEGO – Biosimilar infliximab (Inflectra) was as safe and effective as the original version (Remicade) in an Italian observational cohort study of 547 inflammatory bowel disease (IBD) patients,... (Source: Family Practice News)
Source: Family Practice News - June 20, 2016 Category: Primary Care Source Type: news
Biosimilar therapies for rheumatoid arthritis 'not suitable for all patients'
Biosimilar treatments for rheumatoid arthritis may not be suitable for all patients, according to a new study.Presented at the European League Against Rheumatism's annual congress, the research - led by Progenika Biopharma in Spain - indicated that certain patients who are not able to benefit from treatment with anti-TNF therapies are unlikely to experience a better response by switching to a biosimilar version.The need for better understanding of biosimilars As their name suggests, biosimilar therapies are based on existing licensed drugs and are not identical, but are chemically similar enough to provide equivalent p...
Source: Arthritis Research UK - June 16, 2016 Category: Rheumatology Source Type: news
Inflammatory Arthritis Stable After Switch to BiosimilarInflammatory Arthritis Stable After Switch to Biosimilar
The switch to an infliximab biosimilar was not associated with any change in disease activity or worsening of flares, at least in the short term, new research shows. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 13, 2016 Category: Consumer Health News Tags: Rheumatology News Source Type: news
Biosimilar switching not suitable for all patients
The results of a study showed that when antibodies develop in response to the biological treatment Remicade® (infliximab), they also cross-react with the biosimilar of infliximab (CT-P13: Inflectra® or Remsima®). These findings suggest that antibody-positive patients being treated with Remicade should not be switched to treatment with the biosimilar, since these antibodies will interact with the new drug and potentially lead to a loss of response. , (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - June 9, 2016 Category: Science Source Type: news
Rheumatoid Arthritis - Remicade
Rheumatoid Arthritis - My Doctor Says I Need Remicade (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - June 6, 2016 Category: Journals (General) Source Type: news
Efficacy, Safety of Infliximab and Adalimumab for UCEfficacy, Safety of Infliximab and Adalimumab for UC
Does the latest research recommend infliximab and adalimumab for ulcerative colitis, and are they considered to be both safe and effective? Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 3, 2016 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
